{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T08:06:36Z","timestamp":1790928396943,"version":"4.1.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T00:00:00Z","timestamp":1783728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T00:00:00Z","timestamp":1783728000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s10072-026-09238-3","type":"journal-article","created":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T02:41:49Z","timestamp":1783737709000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Glucagon-like peptide-1 agonists in Parkinson\u2019s disease: a meta-analysis"],"prefix":"10.1007","volume":"47","author":[{"given":"Amr Khalid","family":"Abdallah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Harb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anas","family":"Mansour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asmaa","family":"Nasreldin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rofida","family":"Hamdy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nourhan","family":"Hatem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nada","family":"Mosad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Hamouda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdelrahman","family":"Hamouda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kogulavadanan","family":"Arumaithurai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,11]]},"reference":[{"key":"9238_CR1","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/S1474-4422(24)00038-3","volume":"23","author":"GBD 2021 Nervous System Disorders Collaborators","year":"2024","unstructured":"GBD 2021 Nervous System Disorders Collaborators (2024) Global, regional, and national burden of disorders affecting the nervous system, 1990\u20132021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet Neurol 23:344\u2013381","journal-title":"Lancet Neurol"},{"issue":"s1","key":"9238_CR2","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.3233\/JPD-181474","volume":"8","author":"ER Dorsey","year":"2018","unstructured":"Dorsey ER, Sherer T, Okun MS, Bloem BR (2018) The Emerging Evidence of the Parkinson Pandemic. J Parkinsons Dis 8(s1):S3\u2013S8","journal-title":"J Parkinsons Dis"},{"key":"9238_CR3","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1016\/S0140-6736(21)00218-X","volume":"397","author":"BR Bloem","year":"2021","unstructured":"Bloem BR, Okun MS, Klein C (2021) Parkinson\u2019s disease. Lancet 397:2284\u20132303","journal-title":"Lancet"},{"key":"9238_CR4","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1038\/s41582-024-01034-x","volume":"20","author":"F Stocchi","year":"2024","unstructured":"Stocchi F, Bravi D, Emmi A, Antonini A (2024) Parkinson disease therapy: current strategies and future research priorities. Nat Rev Neurol 20:695\u2013707","journal-title":"Nat Rev Neurol"},{"key":"9238_CR5","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.ncl.2024.12.009","volume":"43","author":"M Fabbri","year":"2025","unstructured":"Fabbri M, Corvol JC, Rascol O (2025) Disease-Modifying Therapies in Parkinson\u2019s Disease. Neurol Clin 43:319\u2013340","journal-title":"Neurol Clin"},{"key":"9238_CR6","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.pneurobio.2016.10.001","volume":"145\u2013146","author":"D Athauda","year":"2016","unstructured":"Athauda D, Foltynie T (2016) Insulin resistance and Parkinson\u2019s disease: A new target for disease modification? Prog Neurobiol 145\u2013146:98\u2013120","journal-title":"Prog Neurobiol"},{"key":"9238_CR7","doi-asserted-by":"publisher","first-page":"775","DOI":"10.3233\/JPD-191900","volume":"10","author":"JLY Cheong","year":"2020","unstructured":"Cheong JLY, de Pablo-Fernandez E, Foltynie T, Noyce AJ (2020) The Association Between Type 2 Diabetes Mellitus and Parkinson\u2019s Disease. J Parkinsons Dis 10:775\u2013789","journal-title":"J Parkinsons Dis"},{"key":"9238_CR8","doi-asserted-by":"publisher","first-page":"3067","DOI":"10.1093\/brain\/awaa262","volume":"143","author":"R Brauer","year":"2020","unstructured":"Brauer R, Wei L, Ma T et al (2020) Diabetes medications and risk of Parkinson\u2019s disease: a cohort study of patients with diabetes. Brain 143:3067\u20133076","journal-title":"Brain"},{"key":"9238_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pneurobio.2014.02.005","volume":"118","author":"F Bassil","year":"2014","unstructured":"Bassil F, Fernagut PO, Bezard E, Meissner WG, Insulin (2014) IGF-1 and GLP-1 signaling in neurodegenerative disorders: targets for disease modification? Prog Neurobiol 118:1\u201318","journal-title":"Prog Neurobiol"},{"key":"9238_CR10","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/1742-2094-5-19","volume":"5","author":"A Harkavyi","year":"2008","unstructured":"Harkavyi A, Abuirmeileh A, Lever R et al (2008) Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson\u2019s disease. J Neuroinflammation 5:19","journal-title":"J Neuroinflammation"},{"key":"9238_CR11","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1038\/s41591-018-0051-5","volume":"24","author":"SP Yun","year":"2018","unstructured":"Yun SP, Kam TI, Panicker N et al (2018) Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson\u2019s disease. Nat Med 24:931\u2013938","journal-title":"Nat Med"},{"key":"9238_CR12","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1016\/S0140-6736(17)31585-4","volume":"390","author":"D Athauda","year":"2017","unstructured":"Athauda D, Maclagan K, Skene SS et al (2017) Exenatide once weekly versus placebo in Parkinson\u2019s disease: a randomised, double-blind, placebo-controlled trial. Lancet 390:1664\u20131675","journal-title":"Lancet"},{"key":"9238_CR13","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1056\/NEJMoa2312323","volume":"390","author":"WG Meissner","year":"2024","unstructured":"Meissner WG, Remy P, Giordana C et al (2024) Trial of Lixisenatide in Early Parkinson\u2019s Disease. N Engl J Med 390:1176\u20131185","journal-title":"N Engl J Med"},{"key":"9238_CR14","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/S1474-4422(23)00378-2","volume":"23","author":"A McGarry","year":"2024","unstructured":"McGarry A, Rosanbalm S, Leinonen M et al (2024) Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson\u2019s disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 23:37\u201345","journal-title":"Lancet Neurol"},{"key":"9238_CR15","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/S0140-6736(24)02808-3","volume":"405","author":"N Vijiaratnam","year":"2025","unstructured":"Vijiaratnam N, Girges C, Auld G et al (2025) Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson\u2019s disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial. Lancet 405:627\u2013636","journal-title":"Lancet"},{"key":"9238_CR16","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1002\/mds.26371","volume":"30","author":"K Kieburtz","year":"2015","unstructured":"Kieburtz K, Olanow CW (2015) Advances in clinical trials for movement disorders. Mov Disord 30:1580\u20131587","journal-title":"Mov Disord"},{"key":"9238_CR17","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1186\/s13098-025-01888-1","volume":"17","author":"MM Helal","year":"2025","unstructured":"Helal MM, AbouShawareb H, Abbas OH et al (2025) GLP-1 receptor agonists in Parkinson\u2019s disease: an updated comprehensive systematic review with meta-analysis. Diabetol Metab Syndr 17:352","journal-title":"Diabetol Metab Syndr"},{"key":"9238_CR18","doi-asserted-by":"publisher","first-page":"5643","DOI":"10.1007\/s10072-025-08411-4","volume":"46","author":"AS Badran","year":"2025","unstructured":"Badran AS, Gbreel MI (2025) From diabetes to dopamine: Evaluating the disease-modifying potential of GLP-1 receptor agonists in Parkinson\u2019s disease. Neurol Sci 46:5643\u20135655","journal-title":"Neurol Sci"},{"key":"9238_CR19","unstructured":"Higgins JPT, Thomas J, Chandler J et al (eds) (2024) Cochrane Handbook for Systematic Reviews of Interventions version 6.5 (updated August 2024). Cochrane"},{"key":"9238_CR20","doi-asserted-by":"publisher","first-page":"105906","DOI":"10.1016\/j.ijsu.2021.105906","volume":"88","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Int J Surg 88:105906","journal-title":"Int J Surg"},{"key":"9238_CR21","doi-asserted-by":"publisher","first-page":"68","DOI":"10.5596\/c14-016","volume":"35","author":"J Babineau","year":"2014","unstructured":"Babineau J (2014) Product Review: Covidence (Systematic Review Software). J Can Health Libr Assoc 35:68\u201371","journal-title":"J Can Health Libr Assoc"},{"key":"9238_CR22","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/1471-2288-14-135","volume":"14","author":"X Wan","year":"2014","unstructured":"Wan X, Wang W, Liu J, Tong T (2014) Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range. BMC Med Res Methodol 14:135","journal-title":"BMC Med Res Methodol"},{"key":"9238_CR23","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:l4898","journal-title":"BMJ"},{"key":"9238_CR24","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/jrsm.1411","volume":"12","author":"LA McGuinness","year":"2021","unstructured":"McGuinness LA, Higgins JPT (2021) Risk-of-bias VISualization (robvis): An R package and Shiny web app for visualizing risk-of-bias assessments. Res Synth Methods 12:55\u201361","journal-title":"Res Synth Methods"},{"key":"9238_CR25","volume-title":"R: A language and environment for statistical computing","author":"R Core Team","year":"2024","unstructured":"R Core Team (2024) R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria"},{"issue":"Suppl 3","key":"9238_CR26","first-page":"III\/21","volume":"249","author":"H Reichmann","year":"2002","unstructured":"Reichmann H (2002) Neuroprotection in idiopathic Parkinson\u2019s disease. J Neurol 249(Suppl 3):III\/21\u2013III\/23","journal-title":"J Neurol"},{"key":"9238_CR27","doi-asserted-by":"publisher","first-page":"114187","DOI":"10.1016\/j.bcp.2020.114187","volume":"180","author":"TS Salameh","year":"2020","unstructured":"Salameh TS, Rhea EM, Talbot K, Banks WA (2020) Brain uptake pharmacokinetics of incretin receptor agonists showing promise as Alzheimer\u2019s and Parkinson\u2019s disease therapeutics. Biochem Pharmacol 180:114187","journal-title":"Biochem Pharmacol"},{"key":"9238_CR28","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1080\/13543784.2020.1738383","volume":"29","author":"C H\u00f6lscher","year":"2020","unstructured":"H\u00f6lscher C (2020) Brain insulin resistance: role in neurodegenerative disease and potential for targeting. Expert Opin Investig Drugs 29:333\u2013348","journal-title":"Expert Opin Investig Drugs"},{"key":"9238_CR29","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1212\/WNL.0000000000009107","volume":"94","author":"AJ Espay","year":"2020","unstructured":"Espay AJ, Kalia LV, Gan-Or Z et al (2020) Disease modification and biomarker development in Parkinson disease: Revision or reconstruction? Neurology 94:481\u2013494","journal-title":"Neurology"},{"key":"9238_CR30","first-page":"CD012990","volume":"7","author":"CA Mulvaney","year":"2020","unstructured":"Mulvaney CA, Duarte GS, Handley J et al (2020) GLP-1 receptor agonists for Parkinson\u2019s disease. Cochrane Database Syst Rev 7:CD012990","journal-title":"Cochrane Database Syst Rev"},{"key":"9238_CR31","doi-asserted-by":"publisher","first-page":"2730","DOI":"10.1172\/JCI68295","volume":"123","author":"I Aviles-Olmos","year":"2013","unstructured":"Aviles-Olmos I, Dickson J, Kefalopoulou Z et al (2013) Exenatide and the treatment of patients with Parkinson\u2019s disease. J Clin Invest 123:2730\u20132736","journal-title":"J Clin Invest"},{"key":"9238_CR32","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1001\/jamaneurol.2015.4265","volume":"73","author":"AM Wills","year":"2016","unstructured":"Wills AM, P\u00e9rez A, Wang J et al (2016) Association Between Change in Body Mass Index, Unified Parkinson\u2019s Disease Rating Scale Scores, and Survival Among Persons With Parkinson Disease. JAMA Neurol 73:321\u2013328","journal-title":"JAMA Neurol"},{"key":"9238_CR33","doi-asserted-by":"publisher","first-page":"8661","DOI":"10.1002\/alz.14313","volume":"20","author":"W Wang","year":"2024","unstructured":"Wang W, Wang Q, Qi X et al (2024) Associations of semaglutide with first-time diagnosis of Alzheimer\u2019s disease in patients with type 2 diabetes: Target trial emulation using nationwide real-world data in the US. Alzheimers Dement 20:8661\u20138672","journal-title":"Alzheimers Dement"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-026-09238-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-026-09238-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-026-09238-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T02:40:18Z","timestamp":1786588818000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-026-09238-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,11]]},"references-count":33,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["9238"],"URL":"https:\/\/doi.org\/10.1007\/s10072-026-09238-3","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,11]]},"assertion":[{"value":"6 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable. This study is a meta-analysis of previously published literature and does not involve new studies with human participants or animals performed by any of the authors.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"620"}}